Mobilo Diagnostics Launches Truenat H3N2/H1N1 Point-of-Care Test

Mobilo Diagnostics announced the release of the Truenat H3N2/H1N1 for the differential diagnosis of the H3N2 and H1N1 viruses. The Central Drugs Standard Control Organization (CDSCO) has approved the test, which may produce results in an hour.

First Point-of-Care Real-Time PCR Test for Confirmed Diagnosis of Influenza Infections

Truenat H3N2/H1N1 is the first point-of-care Real-Time PCR test that aids in the confirmed diagnosis of influenza infections, according to the diagnostics business. The test will run on current Truenat equipment in over 3500 PHCs/CHCs and over 1200 private labs and hospitals across India, allowing patients to receive a rapid diagnosis at all levels of the healthcare chain.

India is now experiencing an increase in influenza virus infections caused by H3N2 and H1N1. The viruses that transmit through the air have the potential to produce an influenza pandemic due to their capacity to maintain human-to-human transmission.

Truenat: A Game Changer in Influenza Diagnosis and Management

“The launch of Truenat H3N2/H1N1 further strengthens Molbio’s product portfolio by providing complete testing solutions for respiratory illnesses. The multi-disease testing capability of the Truenat platform keeps healthcare facilities prepared to combat all kinds of pandemics and disease outbreaks at an early stage. Going forward, Molbio will continue to bring innovative solutions for better patient management and appropriate treatment of the disease,” Sriram Natarajan, CEO, Founder, and Director, of Molbio Diagnostics, said in a statement.

Advantages of Truenat H3N2/H1N1 Test

Truenat, according to the diagnostics firm, has been a game changer in this regard as a point-of-care molecular platform that provides more than 40 tests immediately at the moment of need.